Sumitomo Mitsui Trust Group Inc. lessened its position in McKesson Corporation (NYSE:MCK – Free Report) by 7.0% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 281,119 shares of the company’s stock after selling 21,138 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in McKesson were worth $243,269,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of McKesson by 46.3% during the fourth quarter. Brighton Jones LLC now owns 2,523 shares of the company’s stock valued at $1,438,000 after buying an additional 798 shares in the last quarter. Caxton Associates LLP acquired a new position in McKesson during the first quarter valued at $233,000. Sivia Capital Partners LLC lifted its stake in McKesson by 77.9% in the 2nd quarter. Sivia Capital Partners LLC now owns 685 shares of the company’s stock worth $502,000 after acquiring an additional 300 shares in the last quarter. Treasurer of the State of North Carolina lifted its stake in McKesson by 0.9% in the 2nd quarter. Treasurer of the State of North Carolina now owns 58,623 shares of the company’s stock worth $42,958,000 after acquiring an additional 508 shares in the last quarter. Finally, Osterweis Capital Management Inc. acquired a new stake in McKesson during the 2nd quarter worth about $166,000. Institutional investors and hedge funds own 85.07% of the company’s stock.
Key Stories Impacting McKesson
Here are the key news stories impacting McKesson this week:
- Positive Sentiment: McKesson’s last earnings report beat adjusted EPS estimates and management reaffirmed FY2027 adjusted EPS guidance of $43.80 to $44.60, which supports the company’s longer-term earnings outlook.
- Positive Sentiment: Analyst sentiment remains generally favorable, with a moderate buy consensus and multiple firms maintaining overweight/buy ratings, suggesting Wall Street still sees upside potential.
- Neutral Sentiment: McKesson recently announced its next earnings date for August 5, so investors are likely in a wait-and-see mode ahead of the next quarterly update.
- Neutral Sentiment: The company also disclosed new debt tied to the planned separation of its Medical-Surgical Solutions business, a move that may improve strategic focus but also keeps attention on execution and balance-sheet changes.
- Negative Sentiment: Investors are still reacting to the prior quarter’s revenue shortfall, which outweighed the EPS beat and has kept sentiment cautious around near-term growth.
- Negative Sentiment: Recent leadership turnover, including the planned retirement of Chief Strategy and Business Development Officer Thomas L. Rodgers and a large CEO stock sale under a 10b5-1 plan, may be adding to concerns about insider confidence and continuity.
Insider Buying and Selling at McKesson
McKesson Stock Performance
Shares of MCK opened at $793.32 on Friday. The firm has a market cap of $92.88 billion, a PE ratio of 20.62, a PEG ratio of 1.35 and a beta of 0.31. The firm’s 50 day moving average price is $766.72 and its 200 day moving average price is $838.77. McKesson Corporation has a twelve month low of $637.00 and a twelve month high of $999.00.
McKesson (NYSE:MCK – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $11.69 EPS for the quarter, topping the consensus estimate of $11.56 by $0.13. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. The company had revenue of $96.30 billion during the quarter, compared to the consensus estimate of $101.35 billion. During the same period in the previous year, the firm posted $10.12 earnings per share. The company’s revenue for the quarter was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. On average, sell-side analysts anticipate that McKesson Corporation will post 44.28 earnings per share for the current fiscal year.
McKesson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 1st. Investors of record on Monday, June 1st were issued a $0.82 dividend. The ex-dividend date was Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio is currently 8.53%.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on MCK shares. UBS Group lifted their target price on McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Wells Fargo & Company reduced their price target on shares of McKesson from $925.00 to $812.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Wall Street Zen cut shares of McKesson from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Citigroup lowered their price objective on shares of McKesson from $975.00 to $945.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. Finally, Weiss Ratings lowered shares of McKesson from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $960.53.
Check Out Our Latest Research Report on McKesson
About McKesson
McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.
The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.
Featured Stories
- Five stocks we like better than McKesson
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK – Free Report).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.
